B2Broker Introduces Latest Technology Components of B2Trader Matching Engine as a Software Solution
19.1.2021 13:00:00 EET | Business Wire | Press release
B2Broker, a liquidity and technology provider of solutions for the crypto and Forex industry, has added a new range of features to its matching engine, B2Trader, enabling client demands to be met in record time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005197/en/
Image 1: Screenshot showing users. (Photo: Business Wire)
About B2Trader
B2Trader is used by many of the world's best-known exchanges, MTF Brokers, Security Exchanges, Market Makers, Spot FX Brokers and EMIs, with the job of matching an incoming market order of the user with the existing limit order of another user. The engine works 24/7 in parallel with the round-the-clock rhythm of the crypto markets without any breaks.
Matching - Tech Stack, Details, Scheme of the Module and Capacity
The order matcher is designed for crypto trading and low-latency automatic trading systems and is able to fulfill 10,000 requests per second with an average latency of 500 ms. The new matching engine uses C # ASP.NET Core programming languages for the back-end and includes a trading mechanism for matching orders, various APIs and synchronization services and databases.
API - All Details, Languages and Capacity
The stability and performance aspects of the engine now allow for the development of faster APIs. B2Broker has introduced a new API for robotic trading and public data access which handles trading and public requests much faster while positively affecting the overall system performance (trading and public API - Websocket/Rest). With new API access, users can connect directly into the matching system and operate ultra-fast trading orders or receive crypto markets data on DOMs.
Security
B2Trader incorporates a series of the latest features to provide the best possible protection from technical and fraud threats. These include an anti-throttling system, anti-spoofing protection and DDoS protection. Other security features include 2FA, adding an extra layer of security, and an IP Whitelist which puts in place a restriction to work only under a certain IP inside the admin panel.
Front End
A professional GUI meets all requirements from beginners to pro-traders. It provides a multitude of features and a high degree of customisation including adaptive colouring, easy and highly responsive navigation menu, grouping for sorting options into a more convenient structure and a customisable Dynamic User Interface with colour and font customisation which includes easy addition of widgets, workspaces for various trading styles, widgets customization and workspace arrangement.
Some recent developments include a watchlist that allows for the addition of favourite instruments to monitor percentage changes, White/Night mode, a broad variety of deposit/withdrawal methods featuring B2BinPay, IOC/FOK order settings and the availability of multiple sources of liquidity available for connection with B2Trader.
Back Office
B2Trader admin takes care of all operational options that need to be carried out by the exchange daily, delivering them in a user-friendly and sophisticated manner. The admin module allows you to manage and set up and change exchange user trading/withdrawal permissions, extract information on the history of user logins to the exchange UI, transfer history, user asset balances, information on a user's aggregate balance in indicative currency, setup commissions for the markets or particular user and more, with safety always a top priority.
SAAS AWS
B2Trader uses hosting solutions that dynamically scale resources and support the most demanding and highly loaded projects. AWS hosting offers high levels of availability, scalability and performance, requiring higher amounts of management and administration that is fully organised by B2Broker.
Third-Party Integrations
To set up and run a successful exchange business, there needs to be an equal focus on sales and marketing, compliance, deposits, withdrawals, licenses, and the regulatory framework, etc. To this end, B2Broker has integrated a variety of services that help exchanges manage all aspects effectively. These include B2BinPay, B2Core, Crystal Blockchain, Leading Fiat PSPs, SumSub, B2BX and MarksMan.
The latest features combined with external integrations further enhance B2Trader to deliver a matching engine with the ultimate in performance and functionality, while ensuring that all market participants are given the best execution.
New clients can now benefit from a discount on setup, offering more favourable pricing than 2020 due to COVID and the new market bull run.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005197/en/
Contact information
Rosemary Barnes
Head of PR
pr@b2broker.net
www.b2broker.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom